Keryx Biopharmaceuticals (KERX) : Analyst Rating Update

Keryx Biopharmaceuticals (KERX) : The consensus on Keryx Biopharmaceuticals (KERX) based on 9 analyst recommendation on the company stock is 1.56, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Keryx Biopharmaceuticals (KERX) : The consensus price target for Keryx Biopharmaceuticals (KERX) is $8.75 for the short term with a standard deviation of $2.92. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $13, however, the pessimist price target for the company is $4.

Keryx Biopharmaceuticals (NASDAQ:KERX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.73 and $6.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.95. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.89, notching a gain of 1.17% for the day. The total traded volume was 1,049,830 . The stock had closed at $6.81 on the previous day.

The company shares have dropped -28.84% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $10.80 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $6.06 and the 200 Day Moving Average price is recorded at $4.87.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.